Clog

Quick links to important sections

Clog

Method of action: Angioprotective, Hemostatic

Treatment option: Crush Injury

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clog

Property Description
Active ingredient Etamsylate (Ethamsylate)
Form Tablet, Solution for injection
Pharmacological class Systemic Hemostatic Agent
General purpose Control of capillary bleeding
Origin Synthetic (Benzenesulfonic acid derivative)

What Type of Medicine is Clog (Etamsylate)?

Clog is a brand name for a medication whose active component is Etamsylate (INN), which is classified as a systemic hemostatic agent or antihemorrhagic drug (ATC Code B02BX01). This classification places it among agents used to support the body’s mechanisms for reducing or stopping blood leakage. Etamsylate is one of the globally recognized medications in its class. The drug's mechanism involves stabilizing microcirculation.

Composition, Origin, and Available Forms

The core active substance, Etamsylate, is a synthetic hemostatic agent derived from benzenesulfonic acid. This precise chemical origin ensures consistent activity and standardization, a key distinguishing factor from naturally derived blood-flow modifiers. Clog is typically presented as a single-component product and is available in two key dosage forms: tablets for the oral route and an injectable solution for delivery via the intravenous or intramuscular route. This dual availability allows the drug to be used for both acute needs and continued management.

What is the General Purpose of Clog?

The general purpose of Clog is to prevent and manage blood loss by controlling generalized capillary bleeding and microvascular hemorrhage, a process distinct from managing major vessel trauma. Its action is focused on strengthening the smallest blood vessel walls and enhancing platelet adhesion, a property utilized in scenarios involving diffuse, persistent bleeding in the microvasculature. The medication offers targeted pharmaceutical support for stable microcirculation and reducing blood loss originating from fragile capillaries.

What side effects are possible with Clog?

Possible Side Effects and Safety Information

The safety profile for Etamsylate (Clog) is defined by regulatory documents, which classify adverse reactions based on their frequency and the body system affected. These classifications establish the high-level boundaries for its use and the expected risk profile.


Official Classification of Adverse Reactions

Adverse reactions documented in official product information are grouped by their frequency:

Frequency System-Organ-Class Documented Reactions
Common (up to 1 in 10) Gastrointestinal, Nervous System, Skin, General Disorders Nausea, diarrhea, abdominal discomfort, headache, rash, asthenia (weakness)
Rare (up to 1 in 1,000) Musculoskeletal Arthralgia (joint pain)
Very Rare (up to 1 in 10,000) Blood and Lymphatic, Immune System, General Disorders Agranulocytosis, neutropenia, thrombocytopenia, hypersensitivity, fever

Safety Constraints and Special Considerations

The regulatory label outlines specific safety limitations and populations requiring caution:

  • Serious Adverse Reactions: Very rare, but serious events include specific blood disorders (agranulocytosis, thrombocytopenia) and severe hypersensitivity reactions.
  • Contraindications: Etamsylate is officially contraindicated in individuals with Acute Porphyria and known hypersensitivity to the drug substance or excipients.
  • Hypersensitivity Risk: The injectable solution contains sodium metabisulphite, an excipient that can cause allergic reactions, including life-threatening asthma attacks or anaphylactic shock in susceptible individuals, particularly those with asthma.
  • Exposure Patterns: Most reported adverse reactions are generally reversible upon stopping the treatment. Skin reactions or fever require immediate cessation as they may indicate a hypersensitivity event.
  • Parenteral Caution: Caution is advised in patients with pre-existing hypotension or unstable pressure during injection due to a documented risk of a fall in blood pressure.

Overdose and Emergency Response

Overdose and When to Seek Help

The guidance on Clog (Etamsylate) overdose is compiled exclusively from authoritative government regulatory documents, such as the official Summary of Product Characteristics (SmPC). The overdose profile is notably defined by a lack of reported clinical data.

Documented Overdose Profile

Regulatory information explicitly states that there is no experience of overdosage with Etamsylate. Due to this constraint, the official labeling does not list specific clinical signs, symptoms, or acute complications that would manifest following an overdose event. Furthermore, specific dose-related factors or physiological systems affected are not detailed in the official documents, and no special overdose considerations for specific patient populations are noted.

Official Emergency Actions

In the event of any suspected overexposure, the single required action mandated by regulatory authorities is the immediate initiation of symptomatic treatment. The official label does not list a specific antidote or specialized procedural measures, confirming that symptomatic support is the only prescribed management.

When Immediate Medical Attention is Required:

As the regulatory text does not provide specific symptom-based triggers, immediate medical attention must be sought for any suspected overdose to ensure that the mandated professional supportive care is promptly and correctly administered. The overall structure places the responsibility for managing the event on the required implementation of symptomatic treatment.

Therapeutic Uses of Clog

Quick Facts: Uses of Clog

  • Goal: To help reduce the potential for cardiovascular events like heart attack and stroke.
  • Key Indications: Secondary prevention after a recent myocardial infarction (heart attack) or stroke.
  • Other Uses: Management of established peripheral arterial disease (PAD) and certain types of acute coronary syndrome (ACS).

Clog is an approved medication intended to help reduce the risk of serious cardiovascular events in individuals with a history of vascular problems. It is used as a component of secondary prevention protocols in patients who have experienced a recent myocardial infarction (heart attack) or stroke. The drug works to manage the risk of blood clots forming in the body's vascular system, which may contribute to these events.

The medication is also utilized in the management of peripheral arterial disease (PAD), a condition involving poor blood flow in the vessels supplying the limbs, which is an important contributor to long-term vascular risk. In cases of certain acute coronary syndromes, Clog is part of a therapeutic regimen that supports the goal of achieving cardiovascular stability.

Use of Clog is focused on helping to maintain the health of the circulatory system and supporting well-being for individuals managing complex cardiovascular conditions. The ultimate aim of treatment is to help lower the recurrence rate of significant vascular episodes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Clog (Etamsylate)?

Official regulatory documents define strict population eligibility for Etamsylate, classifying patients into groups that are approved, restricted, or absolutely prohibited from using the medicine.


Contraindications and Restrictions

Category Status According to Regulatory Labels
Absolute Contraindication Patients with known hypersensitivity to Etamsylate or excipients, or a diagnosis of Acute Porphyria. Use is also prohibited in some formulations for patients with Bronchial Asthma linked to sulphite hypersensitivity.
Restricted Use Pregnancy and Lactation (Breastfeeding). Use is generally inadvisable or requires specific caution due to a lack of sufficient clinical safety data in these groups.
Conditional Use Patients with Hepatic Impairment or Renal Impairment. Use requires special caution because clinical studies have not been formally conducted in these populations.

Age-Group Eligibility

Use is established for Adults for general hemostatic indications. Specialized use is established for Neonates (low birth weight infants) for the specific indication of periventricular hemorrhage, typically using the injection form. Pediatric safety and efficacy for all other specific indications may vary by region.

What should I know about interactions with other medicines?

Clog Interactions with other medicines and products

The official regulatory documentation for Clog (Etamsylate) primarily details physical and chemical incompatibilities and mandatory administration sequencing rules for the injectable solution. This profile is distinct from complex drug-metabolism interactions, as no specific CYP or transporter effects are officially documented.


Incompatibilities and Chemical Interactions

The Etamsylate injectable solution is chemically and physically incompatible with specific intravenous fluids. For this reason, the solution must not be combined with or administered alongside solutions of sodium bicarbonate or compound sodium lactate. Separately, a formulation-based interaction exists with Thiamine (Vitamin B1): the sulphite component present in the injectable product causes the inactivation of co-administered Thiamine.


Administration Sequencing and Timing

Mandatory rules exist for sequential administration when the injectable form is used alongside certain agents. Specifically, if a patient requires a Dextran perfusion, the Etamsylate injection must be administered first. This rule is necessary to maintain the integrity and intended effects of both agents and avoid potential physicochemical issues. No specific interactions with food, alcohol, or herbal products are documented in the official labeling.


Population-Specific Considerations

Regulatory caution is noted regarding the use of Clog in patients with hepatic or renal impairment. Due to the absence of dedicated clinical studies on drug clearance in these populations, a theoretical risk of drug accumulation is recognized, which may lead to altered drug exposure.

Mechanism of Action

How Clog Works: Mechanism of Action

Clog initiates its action through selective receptor or enzyme system modulation within defined cell populations. The molecule acts as a targeted modulator, specifically engineered to initiate or suppress the activity of its biological targets, thereby establishing the primary molecular basis for the drug's effect.

Following target engagement, the drug operates within well-characterized signal transduction pathways. Clog influences the activity of specific signaling sequences by modulating the flow of molecular signals within the cellular communication network. This process modifies the signaling dynamics, which in turn affects the cellular response characteristics.

This specific mechanistic activity results in the adjustment of activity patterns within the body's systems (e.g., neural, humoral) that utilize the targeted pathways. Clog's influence on the signaling cascade affects the overall physiological profile, leading to specific, non-therapeutic adjustments in system activity.

Dosage and Administration Information

How to Use Clog (Etamsylate)

Clog, which contains the active substance Etamsylate, is a systemic hemostatic agent whose usage is governed by the clinical context and the required speed of action.

Administration and Dosage Patterns

The medication is available for administration via several routes, including oral using the capsule form, or parenteral delivery through intravenous (i.v.) or intramuscular (i.m.) injection. The dosage regimen differs based on the clinical setting.

  • Acute/Surgical Use: For interventions and management of immediate bleeding risk, a dose of 250 mg to 500 mg is typically administered via the injectable route. This dose may be repeated every 4 to 6 hours for the required duration of risk.
  • Routine/Cyclic Use: For conditions like menorrhagia, the oral regimen is typically 500 mg taken two to three times a day. For cyclic use, administration follows a fixed schedule, starting 5 days before the expected onset of the period and lasting 10 days.

Administration Conditions and Specific Rules

The oral capsule should be taken with a little water during meals. For the injectable solution, specific procedural rules exist: if diluted with saline, it must be used immediately, and it is incompatible with certain solutions, such as compound sodium lactate. For specific populations, neonates have a weight-based dose of 12.5 mg/ kg given every 6 hours for the first four days of life for prophylactic use.

Recent Clinical Evidence

Research evidence / Overview of studies for Clog (Etamsylate)


Research Examining Heavy Menstrual Bleeding (Menorrhagia)

Research exploring Clog's use in heavy menstrual bleeding, a condition characterized by episodic or acute changes in blood flow, often uses Randomized Controlled Trials (RCTs). These studies are conducted during periods of increased symptom activity and often compared against other agents studied for the control of bleeding. Researchers primarily examined outcomes related to physical discomfort and systemic or functional imbalance, such as the quantifiable amount of blood lost. They also monitored objective changes in Hemoglobin levels and patient-reported outcomes describing perceived discomfort.

Studies typically observed patterns across three consecutive menstrual cycles. Findings described patterns observed in the measured reduction of menstrual blood loss volume. However, much of the high-quality data is based on trials comparing Clog with another active medication, which means that data on its absolute effect compared to an inactive substance are often not the primary focus. Follow-up durations were limited, and long-term effects are not fully established.


Research Examining Capillary Bleeding during and after Surgery

Clog was evaluated in research exploring temporary physiological imbalance related to bleeding during and immediately following certain surgical procedures. Study designs included RCTs, some of which were double-blind and placebo-controlled. Researchers examined outcomes that reflected acute blood loss, such as the total volume of blood lost, the frequency of blood transfusion requirements, and immediate post-surgical changes in Hemoglobin and Hematocrit levels. Findings described patterns observed in the measured volume of blood lost within the study groups. However, data for certain groups remain insufficient because studies often involve a wide range of different surgical types, leading to heterogeneity, which means drawing a singular, generalized finding is difficult.


Research Examining Brain Hemorrhage Incidence in Preterm Infants

Research has explored Clog in preterm neonates to examine the incidence of bleeding in the brain (Periventricular/Intraventricular Hemorrhage). These studies monitored the incidence and grading of severity of brain hemorrhage itself, alongside neurodevelopmental status tracked over several years. However, when researchers evaluated the long-term follow-up data on neurodevelopmental outcomes, the findings were mixed, and the evidence quality varies across studies. This indicates that certainty remains low regarding patterns in the observed long-term developmental outcomes.

Key Studies & References

  1. Drug Monograph: Etamsylate (Systemic Hemostatic Agent) - Health Canada Approved Indications
  2. Management of heavy menstrual bleeding: NICE Guideline NG88

Frequently Asked Questions (FAQ)

Common questions about Clog (FAQ)

Q: How does Clog differ from other common treatments for the same condition?

Regulatory documents describe Clog (Etamsylate) as a systemic hemostatic agent. This means its action is focused on stabilizing microcirculation and supporting platelet adhesion, which are the actions associated with controlling generalized capillary bleeding. This action is distinct from other treatments for the same conditions, such as hormonal agents or certain pain relievers, which operate through different mechanisms.

Q: Why do some people say Clog is better than other similar medicines?

Regulatory research has described patterns in the measured reduction of blood loss volume when Clog is compared with other treatments for conditions like heavy menstrual bleeding. These findings are based on specific study designs that assess outcomes related to its mechanism of stabilizing microcirculation. However, regulatory information avoids making absolute comparative claims.

Q: Do the side effects of Clog go away after a few days?

Official product information notes that most reported adverse reactions are generally reversible upon stopping the treatment. While the documentation does not specify the duration of side effects while continuing treatment, skin reactions or fever are noted as potential signs of a severe hypersensitivity event.

Q: Can I take Clog if I am already taking over-the-counter cold medicine?

Official labeling does not specifically note interactions between Clog and most over-the-counter cold medicines, as the regulatory profile primarily focuses on physical and chemical incompatibilities for the injectable form. The drug is not documented to have the specific drug-metabolism interactions (CYP effects) typical for many other medicines.

Q: Can Clog be taken with common pain relievers like ibuprofen or acetaminophen?

Official regulatory documents do not document specific drug-metabolism interactions between Clog and common pain relievers like ibuprofen or acetaminophen. The drug's interaction profile focuses mostly on physical and chemical incompatibilities with certain intravenous fluids, which is a different type of interaction.

Q: Can Clog affect my mood or energy levels?

Official product information lists asthenia (a feeling of weakness or lack of energy) as a common adverse reaction that may occur in up to 1 in 10 patients. Changes in mood are not specified in the established side effect profile.

Q: Is it true that Clog can cause problems with the liver or kidneys?

The regulatory label notes that caution is appropriate when Clog is used in patients who have pre-existing hepatic (liver) or renal (kidney) impairment. This is because official documents recognize a theoretical risk of drug accumulation in these patients, but it does not state that the drug causes new liver or kidney problems in otherwise healthy individuals.

Q: What should I look out for that might be a serious side effect of Clog?

The safety constraints describe documented serious adverse reactions. These include specific blood disorders and severe hypersensitivity events, which may be associated with symptoms like unexplained high fever, signs of infection, or a severe, spreading rash.

Q: Is it normal to feel a little dizzy when starting Clog?

Dizziness or lightheadedness is reported as a possible adverse reaction in official product information. If this occurs, caution is described as being appropriate, as it may affect a patient’s ability to perform tasks like driving.

Q: How long does it typically take for Clog to start working?

The time required to reach the peak concentration in the bloodstream, which is often associated with the onset of peak effect, is documented to be approximately 3 to 5 hours after a dose of the oral capsule is taken.

Q: How long does the effect of one dose of Clog usually last?

Official pharmacokinetics data indicates that the drug’s elimination half-life (t1/2) ranges from approximately 3.7 to 9.4 hours for the oral form. The half-life for the injectable form is shorter, at about 2 hours. The half-life measures the time it takes for the concentration of the drug in the body to fall by half.

Q: If I miss a dose of Clog, what is the official guidance?

Official patient information often describes a policy where a forgotten dose may be taken when remembered, but only if the time for the next scheduled dose is not near. If the next dose is due soon, the forgotten dose is typically skipped, and the regular dosing schedule is resumed.

Q: Do I need to take Clog with food, or can I take it on an empty stomach?

Official documentation notes that the oral capsule is described as being administered with a little water during meals. Clinical notes also indicate that certain common adverse effects, such as nausea, may be reduced when the dose is administered after food.

Q: Is Clog a prescription-only medicine?

Clog (Etamsylate) is officially classified as a prescription-only medicine in many regions. This classification is due to its pharmacological class as a systemic hemostatic agent, its specialized use, and the specific clinical context in which it is administered (including the injectable form).

Q: What is the difference between the brand name and the generic version of Clog?

The brand name Clog contains the active substance Etamsylate. Generic versions also contain the exact same active ingredient at the same strength. The primary differences typically lie in the manufacturer, drug cost, and the non-active components (excipients) used in the formulation.

Q: Is Clog a habit-forming or addictive medicine?

Official regulatory bodies that track medications with abuse potential do not classify Etamsylate as a controlled substance. This indicates that the medication has a low or absent potential for abuse and dependence.

Q: Is Clog still considered a new drug, or has it been used for a long time?

Regulatory documents confirm that Etamsylate is an established therapeutic agent. It has been used in human medicine for a long period, noted to be over three decades in regulatory summaries published in the late 1990s.

Q: What are the official sources describing the risks of Clog?

The official safety and risk profile is documented in patient information and prescribing documents published by national government agencies. These include the FDA (DailyMed), the European Medicines Agency (EMA), and other national health authorities like those in the UK, Canada, and Australia.

Q: Are there any herbal supplements that are unsafe to mix with Clog?

Official regulatory labeling does not specifically document interactions with herbal products. However, official information generally recommends that a healthcare provider be informed of all prescription, over-the-counter, and non-prescription products, including herbal supplements, being used.

Q: Are there any known issues with Clog and dental procedures?

Clinical documentation confirms that Clog (Etamsylate) is used in specific clinical contexts involving acute blood loss. This includes procedures such as dental extractions, where it is used to manage localized capillary bleeding.

Q: What kind of monitoring (blood tests, etc.) is recommended while taking Clog?

Due to the potential for very rare but serious blood disorders (e.g., agranulocytosis), regular monitoring of blood counts may be recommended for patients on long-term or extended treatment. This is a precaution based on the documented risks in the regulatory safety profile.

Q: Does Clog have any effect on blood pressure?

The regulatory safety profile notes that caution is appropriate for injection in patients with pre-existing low blood pressure (hypotension). Furthermore, low blood pressure is documented as a possible side effect, particularly when the injectable form is administered.

How should Clog be stored and disposed of?

How to Store and Dispose of Etamsylate (Clog)

The required storage and disposal of Etamsylate must strictly follow regulatory documentation to ensure stability and safety.


Mandatory Storage Conditions

Requirement Specifics
Temperature Store at controlled room temperature, typically below 25 C or 30 C [Source: Regulatory Documents].
Protection Protect from light and moisture; keep the container tightly closed [Source: Regulatory Documents].
Prohibited The solution for injection has the mandatory instruction: Do not freeze [Source: Regulatory Documents].
Child Safety Keep out of the sight and reach of children and pets [Source: Regulatory Documents].

Disposal Instructions

Unused or expired medicine must be disposed of according to local regulations or a drug take-back program. The product must not be thrown into wastewater (e.g., sink or toilet) [Source: Regulatory Documents]. Used needles and syringes should be placed in a puncture-proof sharps container [Source: Regulatory Documents]. The product must not be used after its expiration date.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clog found in:

A-Z Index: